KR20220087117A - Animal feed additives for enhancing immunity comprising soldier fly and fermented oat mixture - Google Patents
Animal feed additives for enhancing immunity comprising soldier fly and fermented oat mixture Download PDFInfo
- Publication number
- KR20220087117A KR20220087117A KR1020200177500A KR20200177500A KR20220087117A KR 20220087117 A KR20220087117 A KR 20220087117A KR 1020200177500 A KR1020200177500 A KR 1020200177500A KR 20200177500 A KR20200177500 A KR 20200177500A KR 20220087117 A KR20220087117 A KR 20220087117A
- Authority
- KR
- South Korea
- Prior art keywords
- present
- mixture
- feed
- animal feed
- dongae
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 230000036039 immunity Effects 0.000 title claims abstract description 26
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 20
- 235000019730 animal feed additive Nutrition 0.000 title claims description 21
- 241001465754 Metazoa Species 0.000 claims abstract description 13
- 210000000265 leukocyte Anatomy 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 9
- 241000282472 Canis lupus familiaris Species 0.000 abstract description 18
- 239000003674 animal food additive Substances 0.000 abstract description 13
- 230000028709 inflammatory response Effects 0.000 abstract description 2
- 244000075850 Avena orientalis Species 0.000 description 24
- 235000007319 Avena orientalis Nutrition 0.000 description 24
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 230000008859 change Effects 0.000 description 15
- 239000004615 ingredient Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 238000000540 analysis of variance Methods 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 241000709785 Hermetia illucens Species 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004330 calcium propionate Substances 0.000 description 1
- 235000010331 calcium propionate Nutrition 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000010794 food waste Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- -1 glycerin fatty acid ester Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/20—Animal feeding-stuffs from material of animal origin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/12—Animal feeding-stuffs obtained by microbiological or biochemical processes by fermentation of natural products, e.g. of vegetable material, animal waste material or biomass
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Abstract
본 발명은 동애등에와 발효 귀리 혼합물을 포함하는 사료 첨가제 및 이의 면역증강 용도에 관한 것으로, 본 발명의 사료첨가제를 포함하는 사료 조성물을 반려견에게 급여하는 경우, 혈중 백혈구 수준 및 면역 글로불린의 수준이 증가하여 면역력이 증가되면서, 염증 반응이 일어나지 않음을 확인하였다.
본 발명의 사료첨가제는 다방면에 활용되고 있는 동애등에를 활용함으로써 가격이 저렴하면서 면역을 증진시킬 수 있는 사료 첨가제인바, 반려견을 비롯한 동물들의 면역증강용 기능성 사료로서 유용하게 사용될 수 있다.The present invention relates to a feed additive comprising a fermented oat mixture and a fermented oat mixture, and to a use thereof for enhancing immunity. Thus, it was confirmed that the inflammatory response did not occur while the immunity was increased.
The feed additive of the present invention is a feed additive that can enhance immunity while being inexpensive by utilizing Dongae, which is used in various fields, and can be usefully used as a functional feed for enhancing immunity of animals including dogs.
Description
본 발명은 동물사료첨가제와 이를 포함하는 사료 조성물 및 이의 용도에 관한 것으로, 보다 구체적으로, 동애등에 애벌레와 발효 귀리를 혼합하는 혼합물을 포함하는 사료첨가제 및 이의 면역증강용도에 관한 것이다. The present invention relates to an animal feed additive, a feed composition comprising the same, and uses thereof, and more particularly, to a feed additive comprising a mixture of mixing larvae and fermented oats in Dongae, etc., and to a use for enhancing immunity thereof.
면역은 체내에 존재하는 자기방어체계로서 인체가 외부로부터 침입해 오는 각종 물질이나 생명체를 자기 자신에 대한 이물질로 인식하여 제거하고 대사시키는 과정이다. 외부 자극에 의한 손상이나 병원 미생물의 침입으로부터 자신을 방어하기도 하지만 염증반응 등과 같이 자기 자신의 조직에 손상을 줄 수도 있다. 면역기능의 변화를 조절하여 정상으로 회복시키거나 변화의 폭을 줄여 주는 작용으로 면역기능 억제나 면역기능 증강으로 구분된다. 과민면역 반응 완화는 외부 물질에 대해 불리하게 반응하여 초래되는 알레르기 반응 자기항원 또는 변형된 자기항원에 대한 반응 등 바람직하지 않게 증가된 면역 반응을 억제시키는 것을 의미한다.Immunity is a self-defense system that exists in the body, and it is a process in which the human body recognizes and removes and metabolizes various substances or living things that invade from the outside as foreign substances against itself. It protects itself from damage by external stimuli or invasion of pathogenic microorganisms, but it can also damage one's own tissues, such as an inflammatory response. It regulates changes in immune function to restore normalcy or reduces the width of change, and is classified as suppression of immune function or enhancement of immune function. Alleviation of hyperimmune response means suppressing an undesirably increased immune response, such as a response to an allergic reaction self-antigen or a modified self-antigen resulting from an adverse reaction to a foreign substance.
가축이나 애완 동물(이하, 동물이라고 한다) 등에 사용되고 있는 사료는, 분쇄 등의 가공은 이루어지나, 일반적으로 가열 처리 등은 이루어지지 않기 때문에, 소화 흡수율이 낮아져, 사료 효율이 나쁘다는 문제가 있다. 또, 최근에는 인간의 병으로서 알려진 궤양성 대장염이나 크론병 등의 염증성 장관 장애가 동물에서도 보고되어 있고, 설사 등의 증상을 일으킨다는 문제가 있다. 또, 이와 같은 염증성 장관 장애는, 사료의 흡수 저하나 건전 비육을 방해하는 것도 알려져 있다. 동물의 장 내 감염증을 일으키는 병원균으로는, 병원성 대장균, 살모넬라속 세균, 클로스트리듐속 세균, 캄필로박터속 세균 등이 알려져 있다. 이와 같은 병원균은, 이상 증식하면 독소(엔테로톡신, 사이토톡신) 를 생성하고, 장관 점막에 장애를 일으켜, 연변(軟便) 이나 심한 설사 등을 일으키는 것이 알려져 있다. 또, 콕시듐은 닭, 돼지, 소 등의 장관 내에 기생하는 원충으로서, 감염되면 설사, 식욕 부진 등을 일으킨다. 이와 같은 염증성 장관 장애를 예방·치료하기 위하여 항균성 물질이 사용되고 있는데, 약제 내성균의 출현 등의 문제가 있는 것으로 보고 되고 있다.Feeds used for livestock and pets (hereinafter referred to as animals) are processed such as pulverization, but generally are not subjected to heat treatment, so there is a problem in that the digestibility and absorption rate are low and feed efficiency is poor. Moreover, in recent years, inflammatory bowel disorders, such as ulcerative colitis and Crohn's disease, which are known as human diseases, are also reported in animals, and there exists a problem that symptoms, such as diarrhea, are produced. Moreover, it is also known that such an inflammatory bowel disorder interferes with the fall of feed absorption and healthy fattening. As pathogens causing intestinal infections in animals, pathogenic Escherichia coli, bacteria of the genus Salmonella, bacteria of the genus Clostridium, bacteria of the genus Campylobacter, and the like are known. It is known that such pathogens produce toxins (enterotoxin, cytotoxin) when they proliferate abnormally, cause disorders in the intestinal mucosa, and cause soft stool, severe diarrhea, and the like. In addition, coccidium is a parasitic parasite in the intestinal tract of chickens, pigs, cattle, and the like, and when infected, causes diarrhea, loss of appetite, and the like. Antibacterial substances are used to prevent and treat such inflammatory bowel disorders, but it is reported that there is a problem such as the appearance of drug-resistant bacteria.
따라서, 상기와 같은 문제가 없으면서 동물의 면역을 증진시키기 위한 방안이 연구되고 있으며, 흑삼 등의 추출물을 사용하여 반려견의 면역을 증진시키는 조성물을 포함하는 사료 등에 관한 특허는 이미 공개되어 있으나(출원번호: 10-2019-0064943), 이러한 가격이 비싼 흑삼 등의 성분을 포함하기에 높은 가격을 형성할 수 밖에 없다. 이러한 문제를 해결하면서, 유효한 면역증진 효능을 가지는 사료 첨가제 등의 개발이 필요한 실정이다.Therefore, a method for enhancing the immunity of animals without the above problems is being studied, and patents related to a feed including a composition for enhancing the immunity of a dog using an extract such as black ginseng have already been published (application no. : 10-2019-0064943), it has no choice but to form a high price because it contains ingredients such as black ginseng, which is expensive. While solving these problems, there is a need to develop feed additives and the like having an effective immune enhancing effect.
상기와 같은 배경하에, 본 발명자는 면역을 증진시킬 수 있는 사료첨가제를 개발하기위해 연구 노력한 결과, 음식물 처리, 낚시 미끼 등으로 다방면으로 활용되는 동애등에를 활용하여 사료첨가제를 포함하는 사료 조성물을 제조해서 반려견에 급여한 결과, 반려견에서 면역 관련 인자가 증가하는 것을 확인함으로써 본 발명을 완성하였다.As a result of research efforts to develop a feed additive capable of enhancing immunity, the present inventors prepared a feed composition containing a feed additive by utilizing Dongae, which is used in various fields as food treatment, fishing bait, etc. Thus, as a result of feeding the dog, the present invention was completed by confirming that the immune-related factors increase in the dog.
이에, 본 발명은 동애등에 및 발효 귀리 혼합물을 포함하는, 면역증강용 동물사료첨가제를 제공하는 것을 목적으로 한다.Accordingly, an object of the present invention is to provide an animal feed additive for immune enhancement, comprising a mixture of dongae and fermented oats.
또한, 본 발명은 상기 동물사료첨가제를 포함하는, 사료 조성물을 제공하는 것을 다른 목적으로 한다.Another object of the present invention is to provide a feed composition comprising the animal feed additive.
그러나 본 발명이 이루고자 하는 기술적 과제는 이상에서 언급한 과제에 제한되지 않으며, 언급되지 않은 또 다른 과제들은 아래의 기재로부터 당업자에게 명확하게 이해될 수 있을 것이다.However, the technical problem to be achieved by the present invention is not limited to the above-mentioned problems, and other problems not mentioned will be clearly understood by those skilled in the art from the following description.
상기와 같은 본 발명의 목적을 달성하기 위하여, 본 발명은 동애등에 및 발효 귀리 혼합물을 포함하는, 면역증강용 동물사료첨가제를 제공한다.In order to achieve the object of the present invention as described above, the present invention provides an animal feed additive for immune enhancement, comprising a mixture of dongae and fermented oats.
본 발명의 일구현예로, 상기 동애등에는 동애등에 애벌레일 수 있다.In one embodiment of the present invention, the Dongae, etc. may be a caterpillar of Dongae, etc.
본 발명의 다른 구현예로, 상기 혼합물은 백혈구의 수준을 증진시키는 것일 수 있다.In another embodiment of the present invention, the mixture may increase the level of white blood cells.
본 발명의 또 다른 구현예로, 상기 혼합물은 IgG의 수준을 증진시키는 것일 수 있다.In another embodiment of the present invention, the mixture may increase the level of IgG.
본 발명의 또 다른 구현예로, 상기 동물은 개일 수 있다.In another embodiment of the present invention, the animal may be a dog.
또한, 본 발명은 상기 동물사료첨가제를 포함하는 면역증강용 사료 조성물을 제공한다.In addition, the present invention provides a feed composition for enhancing immunity comprising the animal feed additive.
본 발명의 일구현예로, 상기 동물사료첨가제는 5중량% 내지 15중량%로 첨가되는 것을 특징으로 하는, 사료 조성물을 제공한다.In one embodiment of the present invention, the animal feed additive provides a feed composition, characterized in that it is added in an amount of 5% to 15% by weight.
본 발명에서는 동애등에 애벌레와 발효 귀리를 혼합한 혼합물을 제조하여 이를 포함하는 사료 조성물을 급여하는 경우, 반려견의 혈중 백혈구 수치와 면역 글로불린 수준을 증진시키면서 염증반응이 일어나지 않는 것을 확인함으로써 본 발명의 사료첨가제는 면역을 증진시키는 기능성 사료로 사용될 수 있을 것으로 기대된다.In the present invention, when a mixture of larvae and fermented oats is prepared in Dongae, etc. and a feed composition containing it is fed, it is confirmed that an inflammatory reaction does not occur while enhancing the blood white blood cell level and immunoglobulin level of the dog. The additive is expected to be used as a functional feed that enhances immunity.
단, 본 발명의 효과는 상기 효과로 한정되는 것은 아니며, 본 발명의 상세한 설명 또는 청구범위에 기재된 발명의 구성으로부터 추론 가능한 모든 효과를 포함하는 것으로 이해되어야 한다.However, the effect of the present invention is not limited to the above effect, and it should be understood to include all effects that can be inferred from the configuration of the invention described in the detailed description or claims of the present invention.
도 1은 본 발명의 혼합물을 포함하는 사료를 급여한 다음, 시간경과에 따라 소형견의 혈중 IgG 농도 변화율을 확인한 결과이다.1 is a result of confirming the change rate of the blood IgG concentration of small dogs over time after feeding a feed containing a mixture of the present invention.
본 발명자들은 면역을 증진시킬 수 있는 조성물을 발굴하기 위해 연구 노력한 결과, 동애등에와 발효귀리를 혼합하여 혼합물을 제조할 수 있었고, 제조된 혼합물을 포함하는 사료첨가제를 포함하는 사료 조성물을 급여한 반려견에서 면역 관련 인자가 증가하는 것을 확인하였는바, 이로써 본 발명을 완성하게 되었다.As a result of research efforts to discover a composition that can enhance immunity, the present inventors were able to prepare a mixture by mixing fermented oats with Dongae, etc., and a dog fed a feed composition containing a feed additive including the prepared mixture It was confirmed that the immune-related factors increase in the bar, thereby completing the present invention.
이에, 본 발명은 동애등에 및 발효 귀리 혼합물을 포함하는, 면역증강용 동물사료첨가제를 제공한다.Accordingly, the present invention provides an animal feed additive for enhancing immunity, comprising a mixture of dongae and fermented oats.
본 발명에 있어서 동애등에(Black soldier fly)는 2~30 mm로 매우 작은 크기의 곤충이며 맨 끝이 고리 모양인 3분절의 더듬이가 달려 있고, 전세계에 400 내지 1500 여 종이 널리 퍼져 분포하고 있는 것으로 알려져 있다. 동애등에를 이용하여 음식물 쓰레기를 처리하는 기술이 개발되어 사용되고 있으며, 동애등에는 칼슘 등의 성분이 풍부하여 생먹이로 판매되기도 한다. 본 발명의 혼합물에 사용된 동애등에는 애벌레일 수 있으며, 이에 제한되는 것은 아니지만, 국립농업과학원에서 생산한 동애등에일 수 있다.In the present invention, black soldier fly is a very small insect with a size of 2 to 30 mm, and has a ring-shaped three-segment antenna at the end, and 400 to 1500 species are widely distributed around the world. is known A technology for processing food waste using Dongae, etc. has been developed and used, and Dongae, etc. is rich in calcium and other ingredients, so it is sometimes sold as live food. Dongae, etc. used in the mixture of the present invention may be a caterpillar, but is not limited thereto, and may be Dongae, etc. produced by the National Academy of Agricultural Sciences.
본 발명에 있어서, 발효 귀리(Fermented Oat)는 귀리를 발효한 것으로서, 통상적으로 곡류의 발효에 사용되는 방법을 통해 발효된 것일 수 있다. 본 발명에 있어서 발효 방법은 비연속 발효, 유가 배양식 발효, 개방 발효 또는 연속 발효 등일 수 있으며, 본 발명의 발효귀리는 보란애니멀헬스에서 제공한 발효귀리를 사용하였으나, 이에 제한되는 것은 아니다.In the present invention, fermented oats (Fermented Oat) are fermented oats, and may be fermented through a method commonly used for fermentation of grains. In the present invention, the fermentation method may be discontinuous fermentation, fed-batch fermentation, open fermentation or continuous fermentation, and the fermented oats of the present invention are fermented oats provided by Boran Animal Health, but are not limited thereto.
본 발명에 있어서 사용되는 용어 "면역증강"은 면역과 관련된 인자가 증진되는 것을 의미하는 것으로서, 이에 제한되는 것은 아니지만, 백혈구, 면역 관련 사이토카인, 이뮤노글로불린 등이 수준이 변화하여 면역이 증진되는 것을 의미한다.As used in the present invention, the term "immune enhancement" means that factors related to immunity are enhanced, and is not limited thereto, but the level of leukocytes, immune-related cytokines, immunoglobulins, etc. is changed to enhance immunity. means that
본 발명에 있어서 상기 혼합물은 혈중 백혈구(White blood cell, WBC)의 수준을 정상범위내에서 유의적으로 증진시키는 것일 수 있으며, 면역과 관련된 이뮤노글로불린인 IgG의 혈중 수준을 증진시키는 것일 수 있다. 이러한 결과를 통해 본 발명의 동애등에 및 발효 귀리 혼합물은 면역력을 증진시켜 면역증강용 기능성 사료첨가제 등으로 유용하게 활용될 수 있다.In the present invention, the mixture may significantly increase the level of white blood cells (WBC) within the normal range, and may enhance the blood level of IgG, an immunoglobulin related to immunity. Through these results, the fermented oat mixture of the present invention can be effectively used as a functional feed additive for enhancing immunity by enhancing immunity.
본 발명에 있어서, 구체적인 실시예를 통해 본 발명의 동애등에 및 발효 귀리 혼합물이 반려견의 면역을 유효하게 증진시킨다는 사실을 확인하였다.In the present invention, through specific examples, it was confirmed that the fermented oat mixture and dongae etc. of the present invention effectively enhance the immunity of dogs.
본 발명의 일실시예에 있어서, 본 발명의 혼합물을 포함하는 동물사료첨가제를 기초사료와 배합하여 소형견 20두에 처리하고 혈중 백혈구 수준(실시예 2-1 참조) 및 혈중 IgG 수준(실시예 2-2 참조)를 확인한 결과, 백혈구 및 IgG의 수준이 모두 증가된 것으로 확인할 수 있었다.In one embodiment of the present invention, the animal feed additive containing the mixture of the present invention is mixed with basic feed and treated in 20 small dogs, and the blood leukocyte level (see Example 2-1) and the blood IgG level (Example 2) -2), it was confirmed that the levels of white blood cells and IgG were both increased.
본 발명의 다른 실시예에 있어서, 본 발명의 혼합물을 포함하는 동물사료첨가제를 기초사료와 배합하여 소형견 20두에 처리하고 염증성 사이토카인의 발현 수준을 확인한 결과, 염증성 사이토카인이 유의한 발현 변화를 보여주지 않았다(실시예 2-3 참조).In another embodiment of the present invention, the animal feed additive containing the mixture of the present invention was mixed with basic feed and treated in 20 small dogs and the expression level of inflammatory cytokines was confirmed. not shown (see Examples 2-3).
상기와 같은 결과를 통해 본 발명의 발명자들은 본 발명의 혼합물을 포함하는 동물사료첨가제는 동물의 면역을 유효하게 증진시키면서도 염증반응을 보여주지 않는 것을 확인할 수 있었고, 이를 통해 동물의 면역을 증진시켜주는 기능성 동물사료첨가제로서 유용하게 활용될 수 있다는 사실을 확인하였다.Through the above results, the inventors of the present invention were able to confirm that the animal feed additive containing the mixture of the present invention does not show an inflammatory reaction while effectively enhancing the animal's immunity, and through this, It was confirmed that it can be usefully used as a functional animal feed additive.
또한, 본 발명의 일 양태에 있어서, 본 발명은 상기 동물사료첨가제를 포함하는 면역증강용 사료조성물을 제공한다.Further, in one aspect of the present invention, the present invention provides a feed composition for enhancing immunity comprising the animal feed additive.
본 발명에 있어서, 상기 동물사료첨가제는 사료 조성물에 5중량% 내지 15중량%의 성분비로 포함되는 것일 수 있으며, 바람직하게는 10중량% 내지 15중량%의 성분비로 포함될 수 있다.In the present invention, the animal feed additive may be included in a component ratio of 5 wt% to 15 wt% in the feed composition, preferably 10 wt% to 15 wt%.
본 발명에 있어서, 상기 사료 조성물은 본 발명의 사료 첨가제 외에, 동물의 성장 촉진에 유효한 성분, 영양 성분, 영양 보조 성분, 보존안정성을 높이는 성분, 피복제 성분 등의 임의 성분을 추가 포함할 수 있다. 사료 조성물은, 다른 생균제; 아밀라아제, 리파아제 등의 효소; L-아스코르브산, 염화콜린, 이노시톨 등의 비타민; 염화칼륨, 시트르산철, 산화마그네슘, 인산염류 등의 미네랄; 리신, 알라닌, 메티오닌 등의 아미노산; 푸마르산, 부티르산, 락트산 등의 유기산 또는 이의 염; 비타민 C, 비타민 E 등의 항산화제, 프로피온산칼슘 등의 곰팡이 방지제; 레시틴, 글리세린 지방산 에스테르 등의 유화제; 색소 등을 포함할 수 있다.In the present invention, the feed composition may further include optional ingredients such as ingredients effective for promoting animal growth, nutritional ingredients, nutritional supplement ingredients, ingredients for enhancing storage stability, and coating ingredients, in addition to the feed additives of the present invention. . The feed composition may include other probiotics; enzymes such as amylase and lipase; vitamins such as L-ascorbic acid, choline chloride, and inositol; minerals such as potassium chloride, iron citrate, magnesium oxide, and phosphates; amino acids such as lysine, alanine, and methionine; organic acids or salts thereof, such as fumaric acid, butyric acid, and lactic acid; antioxidants such as vitamin C and vitamin E, and fungicides such as calcium propionate; emulsifiers such as lecithin and glycerin fatty acid ester; Colors and the like may be included.
본 발명에 있어서, 상기 사료 조성물은 동물 사료 조성물일 수 있고, 구체적으로 소, 물소, 산양, 양, 염소 또는 사슴에 대한 사료 조성물 일 수 있으나, 이에 제한되는 것은 아니다. 섭취시키는 사료의 양은 동물의 종류, 체중, 연령, 성별, 건강 상태, 사료의 성분 등에 따라 적절히 조절할 수 있다.In the present invention, the feed composition may be an animal feed composition, specifically, may be a feed composition for cattle, buffalo, goats, sheep, goats or deer, but is not limited thereto. The amount of feed to be ingested can be appropriately adjusted according to the type of animal, body weight, age, sex, health status, ingredients of the feed, and the like.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시한다. 그러나 하기의 실시예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 하기 실시예에 의해 본 발명의 내용이 한정되는 것은 아니다.Hereinafter, preferred examples are presented to help the understanding of the present invention. However, the following examples are only provided for easier understanding of the present invention, and the contents of the present invention are not limited by the following examples.
[실시예][Example]
실시예 1. 발효 귀리 및 동애등에 혼합물의 제조Example 1. Preparation of a mixture of fermented oats and dongae
본 발명 혼합물의 면역증진 효과를 확인하기 위해, 시험사료 무처리 구(CON); 발효 귀리 포함하는 시험사료 첨가 구(Fermented Oat, FO)(보란애니멀헬스); 동애등에 애벌레 시험사료 첨가 구(Black soldier fly larvae, BSFL)(국립농업과학원); 및 동애등에 애벌레 및 발효귀리 시험사료 첨가 구(Fermented Oat + Black soldier fly larvae, FO+BSFL)로 나누어 혼합물을 준비하였다. 상기 기초사료 및 시험사료 첨가제의 구체적인 성분은 하기 표 1에 나타내었으며, 기초사료와 시험사료의 혼합비는 하기 표 2에 나타내었다.In order to confirm the immune-enhancing effect of the mixture of the present invention, test feed untreated Gu (CON); Fermented Oat, FO, containing fermented oats (Boran Animal Health); Gu (Black soldier fly larvae, BSFL) (National Academy of Agricultural Science); And larvae and fermented oat test feed addition gu (Fermented Oat + Black soldier fly larvae, FO + BSFL) to Dongae, etc. to prepare a mixture. Specific components of the basic feed and test feed additives are shown in Table 1 below, and the mixing ratio of the basic feed and test feed is shown in Table 2 below.
실시예 2. 본 발명의 혼합물의 면역증강 효과 확인Example 2. Confirmation of immune enhancing effect of the mixture of the present invention
2-1. 혈중 백혈구 수준 확인2-1. Checking the level of white blood cells in the blood
본 발명의 혼합물이 면역증강 효과를 가진다는 사실을 확인하기 위해 소형견(10세)(성견의 몸무게가 10kg 미만인 개) 20두에게 본 발명의 혼합물을 포함하는 사료를 급여한 다음, 혈액내에 백혈구(White blood cell, WBC) 수준을 확인하였다. 사료는 체중에 기반하여 급여하였고, 이에 따른 일당 사료 섭취량(Average daily feed intake, ADFI)은 하기 표 3에 나타내었다. 본 발명의 혼합물 사료 첨가제는 수분 함량이 높아 건물기준 에너지 요구량을 충족시키기 위해 대조구 보다 일당 사료 섭취량이 높게 나왔으나, 총 건물 에너지 섭취량은 유사하게 하여 급여하였다.In order to confirm that the mixture of the present invention has an immune enhancing effect, 20 small dogs (10 years old) (dogs weighing less than 10 kg of adult dogs) are fed a feed containing the mixture of the present invention, and then leukocytes ( White blood cell, WBC) level was confirmed. The feed was fed based on body weight, and the average daily feed intake (ADFI) accordingly was shown in Table 3 below. The mixture feed additive of the present invention had a high water content, so the daily feed intake was higher than that of the control group to meet the dry energy requirement, but the total dry energy intake was similarly fed.
상기와 같이 사료를 급여하고, 혈액내 백혈구 수치를 혈구분석기(VetScanHM5, ABAXIS, USA)와 이에 활용되는 혈구분석 Kit(VetScanHM5 reagent pack(HM reagent pack 770-9000))를 사용하여 분석하여 백혈구 수치를 하기 표 4에 나타내었다.Feed the feed as described above, and analyze the white blood cell count in the blood using a hemocytometer (VetScanHM5, ABAXIS, USA) and a blood cell analysis kit (VetScanHM5 reagent pack (HM reagent pack 770-9000)) to determine the white blood cell count. It is shown in Table 4 below.
상기 12w/0w은 개체별 0주차 혈중 WBC 수준을 100%로 환산하여 12주차의 혈중 WBC 변화율을 각 개체별로 산출한 이후 평균으로 계산한 결과 값을 의미한다. 상기 표 4에서 급여효과에 대한 분산 분석 유의성은 ANOVA로 확인하였고, 시간 경과에 따른 처리 급여 효과는 R-ANOVA로 확인하였다. 소형견의 WBC의 혈중 농도는 시간경과에 따라 대조구에서는 평균 7.4% 감소하였으나, 발효귀리, 동애등에, 혼합물 급여구에서는 0주차 대비 12주차에서는 각각 평균 20.1%, 18.4%, 22.2% 증가하였다. 다만, 개체별 개시시점에서의 혈중 WBC 농도가 상이하여 개체별 개시시점의 WBC 수준을 각각 100%로 환산하여 12주차의 WBC 변화율을 각 개체별로 산출하여 평균값을 도출한 결과, 대조구에서는 0주차 대비 93.5% 수준으로 나타났으며, 발효귀리, 동애등에, 혼합물 급여구는 각각 0주차 대비 12주차에 118%, 143%, 125% 수준으로 통계적으로 유의하게 증가되는 것을 관찰하였다. 본 발명의 사료 첨가제를 처리한 사료를 급여하는 경우 혈중 면역관련 세포의 수가 정상 범위 내에서 대조구 대비 개선되는 것으로 확인할 수 있었다.The 12w/0w denotes a result value calculated as an average after calculating the blood WBC change rate at week 12 for each individual by converting the blood WBC level at week 0 for each individual to 100%. In Table 4, the significance of the analysis of variance for the benefit effect was confirmed by ANOVA, and the treatment benefit effect over time was confirmed by R-ANOVA. The plasma concentration of WBC in small dogs decreased by an average of 7.4% in the control group over time, but increased by an average of 20.1%, 18.4%, and 22.2% in the group fed with fermented oats, dongae, and mixtures at the 12th week compared to the 0th week, respectively. However, since the blood WBC concentration at the initiation time of each individual is different, the WBC level at the initiation time of each individual is converted to 100%, and the WBC change rate at the 12th week is calculated for each individual and the average value is derived. 93.5% level, and it was observed that fermented oats, dongae, etc., and mixture fed groups increased statistically significantly to 118%, 143%, and 125% levels at 12 weeks compared to 0 weeks, respectively. When the feed treated with the feed additive of the present invention was fed, it was confirmed that the number of immune-related cells in the blood was improved compared to the control group within the normal range.
2-2. 혈중 IgG 수준 확인2-2. Check your blood IgG level
본 발명 혼합물이 면역에 관여하는 면역글로불린의 발현을 증진시킬 수 있는지 여부를 사실을 확인하기 위해 실시예 2-1에서 준비한 소형견 20 두에게 본 발명의 혼합물을 포함하는 사료를 급여한 다음, 혈중 면역글로불린 G(IummunoIglobulin G, IgG)의 수준을 확인하였다. IgG의 수준을 측정하기 위해 Microplate reader 및 Canine IL-10 Immunoassay kit(SEKC-0026, Solarbio, China)를 사용하였으며, 이렇게 측정한 결과를 하기 표 5에 나타내었다.In order to confirm whether the mixture of the present invention can enhance the expression of immunoglobulin involved in immunity, feed containing the mixture of the present invention to 20 small dogs prepared in Example 2-1 is fed, and then blood immunity The level of globulin G (IummunoIglobulin G, IgG) was confirmed. Microplate reader and Canine IL-10 Immunoassay kit (SEKC-0026, Solarbio, China) were used to measure the level of IgG, and the measurement results are shown in Table 5 below.
같은 열에서 동일한 어깨문자(a, b)를 포함하지 않는 데이터는 처리구 간에 통계적으로 유의성이 있으며(p<0.05), Change rate는 개체별 0주차 혈중 IgG 수준을 100%로 환산하여 각 주차별 혈중 IgG 변화율을 각 개체별로 산출한 이후 평균으로 계산한 결과 값을 의미한다. Data that do not contain identical shoulder characters ( a, b ) in the same column are statistically significant between treatments (p<0.05), Change rate refers to the result of calculating the blood IgG change rate for each individual by converting the blood IgG level at week 0 for each individual to 100% and calculating the average value after calculating the change rate for each individual.
실험 결과, 상기 표 5에 나타낸 바와 같이, 혈중 면역글로블린 G를 분석한 결과 모든 처리구에서 유의한 차이는 관찰되지 않았으나, 시간경과에 따른 변화량을 분석한 결과 도 1에 나타낸 바와 같이, 발효귀리 및 동애등에 혼합물의 급여한 경우가 시험 4주차에 유의하게 높은 증가율을 보였다. 12주차까지 유의한 차이는 없었으나, 대조구 대비 개시시점 보다 높은 증가율의 결과를 나타내는 것을 확인할 수 있었으며, 이와 같은 결과를 바탕으로 대조구와 혼합물 급여구에 대한 Paired t-test를 진행하였고, 그 결과를 하기 표 6에 나타내었다.As a result of the experiment, as shown in Table 5 above, no significant difference was observed in all treatment groups as a result of analyzing blood immunoglobulin G, but as a result of analyzing the amount of change over time, as shown in FIG. The case where the mixture was fed to the back showed a significantly higher increase rate at the 4th week of the test. There was no significant difference until the 12th week, but it was confirmed that the result showed a higher rate of increase compared to the control group. It is shown in Table 6 below.
Change rate는 개체별 0주차 혈중 IgG 수준을 100%로 환산하여 각 주차별 혈중 IgG 변화율을 각 개체별로 산출한 이후 평균으로 계산한 결과 값을 의미한다.Change rate refers to the result of calculating the blood IgG change rate for each individual by converting the blood IgG level at week 0 for each individual to 100% and calculating the average value after calculating the change rate for each individual.
혈중 IgG 농도에 대하여 대조구와 혼합물 급여구간의 시간경과에 따른 변화를 분석한 결과, 대조구에서는 12주차에 0주차 대비 평균 약 14.7%가 감소되는 것으로 나타났으나, 발효귀리 및 동애등에 혼합물 급여구에서는 0주차 대비 12주차에 약 18%가 통계적으로 유의하게 증가하였다. 다만, 개체별 개시시점에서의 혈중 IgG 농도가 상이하여 개체별 개시시점의 IgG 수준을 각각 100%로 환산하여 각 주차별 IgG 변화율을 각 개체별로 산출하여 평균값을 도출한 결과, 대조구에서는 0주차 대비 72.1% 수준으로 나타났으며, 발효귀리 및 동애등에 혼합물 급여구는 0주차 대비 12주차에 153% 수준으로 통계적으로 유의하게 증가되는 것을 확인할 수 있었다.As a result of analyzing the change over time between the control group and the mixture feeding interval with respect to the blood IgG concentration, it was found that an average of about 14.7% decreased at 12 weeks compared to 0 weeks in the control group, but in the group fed with fermented oats and dongae, etc. There was a statistically significant increase of about 18% at week 12 compared to week 0. However, since the blood IgG concentration at the initiation time of each individual is different, the IgG level at the initiation time of each individual is converted to 100%, and the IgG change rate for each week is calculated for each individual and the average value is derived. It was found to be at the 72.1% level, and it was confirmed that the group fed with a mixture of fermented oats and dongae was statistically significantly increased to a level of 153% at the 12th week compared to the 0th week.
2-3. 혈중 염증성 사이토카인 수준 확인2-3. Checking the level of inflammatory cytokines in the blood
본 발명 혼합물이 면역 관련 사이토카인의 발현을 증진시킬 수 있는지 여부와 실시예 2-1과 2-2의 혼합물 급여에 의한 WBC 및 IgG 증가가 염증의 유발에 의한 결과인지에 대한 여부를 확인하기 위해 실시예 2-1에서 준비한 소형견 20두 두에게 본 발명의 혼합물을 포함하는 사료를 급여한 다음, 염증성 사이토카인(TNF-α 및 IL-10)의 수준을 확인하였다. 염증성 사이토카인의 수준을 측정하기 위해 Microplate reader 사용하였으며, TNF-α를 측정하기 위해 Canine TNF-α Immunoassay kit(SEKC-0033, Solarbio, China)을 사용하였고, IL-10을 측정하기 위해 Canine IL-10 Immunoassay kit(SEKC-0026, Solarbio, China)를 사용하였다. 이렇게 측정한 결과를 하기 표 7에 나타내었다.To determine whether the mixture of the present invention can enhance the expression of immune-related cytokines and whether the increase in WBC and IgG by feeding the mixture of Examples 2-1 and 2-2 is a result of the induction of inflammation After feeding the feed containing the mixture of the present invention to 20 heads of small dogs prepared in Example 2-1, the level of inflammatory cytokines (TNF-α and IL-10) was checked. Microplate reader was used to measure the level of inflammatory cytokines, Canine TNF-α Immunoassay kit (SEKC-0033, Solarbio, China) was used to measure TNF-α, and Canine IL- to measure IL-10 10 Immunoassay kit (SEKC-0026, Solarbio, China) was used. The measurement results are shown in Table 7 below.
염증관련 사이토카인의 수준을 확인한 결과, TNF-α 및 IL-10의 농도는 전체 시험기간 동안 시간 경과별, 시험 사료 급여별로 분석했을 때, 통계적으로 유의미한 차이는 관찰되지 않았다. 이와 같은 결과는 발효귀리 및 동애등에 혼합물 급여에 의한 면역지표(WBC, IgG)의 개선이 염증유발에 의한 결과가 아님을 증명한다. 이와 같은 결과를 통해 본 발명의 발명자들은 발효귀리 및 동애등에 혼합물을 반려견에 급여하는 경우 염증을 유발하지 않으면서 혈중 면역력을 증진시킬 수 있는 것으로 판단하였다.As a result of confirming the level of inflammation-related cytokines, no statistically significant difference was observed in the concentrations of TNF-α and IL-10 during the entire test period when analyzed by time course and test feed feeding. These results prove that the improvement of immune indicators (WBC, IgG) by feeding mixtures of fermented oats and Dongae, etc. is not a result of inflammation. Through these results, the inventors of the present invention judged that when a mixture of fermented oats and Dongae, etc. is fed to a dog, it is possible to enhance blood immunity without causing inflammation.
상기 진술한 본 발명의 설명은 예시를 위한 것이며, 본 발명이 속하는 기술분야의 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 쉽게 변형이 가능하다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다.The description of the present invention stated above is for illustration, and those of ordinary skill in the art to which the present invention pertains can understand that it can be easily modified into other specific forms without changing the technical spirit or essential features of the present invention. There will be. Therefore, it should be understood that the embodiments described above are illustrative in all respects and not restrictive.
Claims (7)
Animal feed additive for immune enhancement, including Dongae and fermented oat mixture.
상기 동애등에는 동애등에 애벌레인 것을 특징으로 하는, 동물사료첨가제.
The method of claim 1,
The dongae, etc., characterized in that the larvae of dongae, etc., animal feed additives.
상기 혼합물은 백혈구의 수준을 증진시키는 것을 특징으로 하는, 동물사료첨가제.
The method of claim 1,
The mixture is characterized in that for enhancing the level of white blood cells, animal feed additive.
상기 혼합물은 IgG의 수준을 증진시키는 것을 특징으로 하는, 동물사료첨가제.
The method of claim 1,
The mixture is characterized in that to enhance the level of IgG, animal feed additive.
상기 동물은 개인 것을 특징으로 하는, 동물사료첨가제.
The method of claim 1,
The animal is characterized in that the individual, animal feed additive.
A feed composition for enhancing immunity, comprising the animal feed additive of any one of claims 1 to 5.
상기 동물사료첨가제는 5중량% 내지 15중량%로 첨가되는 것을 특징으로 하는, 사료 조성물.
7. The method of claim 6,
The feed composition, characterized in that the animal feed additive is added in an amount of 5% to 15% by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200177500A KR20220087117A (en) | 2020-12-17 | 2020-12-17 | Animal feed additives for enhancing immunity comprising soldier fly and fermented oat mixture |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200177500A KR20220087117A (en) | 2020-12-17 | 2020-12-17 | Animal feed additives for enhancing immunity comprising soldier fly and fermented oat mixture |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220087117A true KR20220087117A (en) | 2022-06-24 |
Family
ID=82215632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200177500A KR20220087117A (en) | 2020-12-17 | 2020-12-17 | Animal feed additives for enhancing immunity comprising soldier fly and fermented oat mixture |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20220087117A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102560174B1 (en) | 2022-07-08 | 2023-07-26 | 농업회사법인 그린미소 주식회사 | Preparaion method of animal feed additives including soldier fly |
-
2020
- 2020-12-17 KR KR1020200177500A patent/KR20220087117A/en not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102560174B1 (en) | 2022-07-08 | 2023-07-26 | 농업회사법인 그린미소 주식회사 | Preparaion method of animal feed additives including soldier fly |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nemec et al. | Immune responses in lactating Holstein cows supplemented with Cu, Mn, and Zn as sulfates or methionine hydroxy analogue chelates | |
| Cromwell | Antimicrobial and promicrobial agents | |
| Kegley et al. | Bill E. Kunkle interdisciplinary beef symposium: impact of mineral and vitamin status on beef cattle immune function and health | |
| EP1902724A2 (en) | Antimicrobial compositions | |
| Gamko et al. | Productivity and parameters of blood of sows fed with probiotic supplements | |
| Michalak et al. | The effect of metal-containing nanoparticles on the health, performance and production of livestock animals and poultry | |
| Zhang et al. | Effect of dietary supplemental medium chain fatty acids instead of antibiotics on the growth performance, digestibility and blood profiles in growing pigs | |
| Wang et al. | Effects of sodium humate and glutamine combined supplementation on growth performance, diarrhea incidence, blood parameters, and intestinal microflora of weaned calves | |
| WO2023014651A1 (en) | Products and methods for inhibiting respiratory conditions | |
| Aremmt et al. | Study the Role of Selenium or Zinc as Organic form on some Antioxidant and Liver Enzymes of Rams. | |
| KR20220087117A (en) | Animal feed additives for enhancing immunity comprising soldier fly and fermented oat mixture | |
| KR20220086987A (en) | Animal feed additive for cholesterol reduction, comprising soldier fly | |
| RU2285399C1 (en) | Method for increasing meat productivity of youngsters in fattening swine | |
| Pormalekshahi et al. | Interaction effect of ruminal undegradable protein level and rumen-protected conjugated linoleic acid (CLA) inclusion in the diet of growing goat kids on meat CLA content and quality traits | |
| Dick et al. | Effects of a direct-fed microbial on digestive-tract morphology of Holstein bull calves and performance and carcass characteristics of Holstein steers | |
| Marwan et al. | Influence of basil oil as an essential oil on buffalo calves performance, digestibility, haemobiochemical profile and rumen fermentation indicators | |
| US20200305461A1 (en) | Bacteriophage animal feed preservative | |
| Mallaki et al. | The effect of bovine lactoferrin and probiotic on performance and health status of Ghezel lambs in preweaning phase. | |
| Boorboor et al. | Effects of reducing crude protein concentration in starter feed containing constant rumen undegradable protein on dairy calves performance | |
| Moturi et al. | Effects of dietary arginine in ameliorating the deleterious effects induced by mycotoxins on growth, immune system, body organs in growing pigs | |
| Dharmayudha et al. | Soil worms (Lumbricus rubellus) as feed additives for piglets' growth, blood profile and immunomodulators | |
| Han et al. | Effects of different selenium sources and levels on serum biochemical parameters and tissue selenium retention in rats | |
| El-Kholy et al. | Study on the optimal crude papaya latex content of growing rabbit diet under summer conditions: Effects on growth performance and immune status | |
| Josiane et al. | Effects of Methenamine Feeding Regime on Growth Performances, Gut Microbiota, Organs Histology and Haemato-Biochemical Profile of Broiler Chickens | |
| Maroccolo | Inclusion of a species-specific probiotic or calcium diformate in young calves diets: effects on gut microbial balance, health status and growth performance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |